	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	471	482	557	385	580	711	983	1,685	1,894	1,967	2,184	2,217	2,133	2,079	2,319	2,524
Cost of Operating Revenue	383	383	452	308	443	507	725	1,099	1,120	1,163	1,640	1,623	1,486	1,486	1,596	1,683
Gross Profit	88	98	105	77	137	203	258	586	774	804	544	594	647	593	723	841
Gross Margin	18.7	20.4	18.8	19.9	23.6	28.6	26.2	34.8	40.9	40.9	24.9	26.8	30.3	28.5	31.2	33.3
Total Operating Expenses	426	424	499	402	559	638	893	1,308	1,356	1,414	1,968	2,037	1,965	1,949	2,130	2,295
Operating Profit	45	58	58	-18	22	73	90	377	538	553	216	180	168	130	190	229
Operating Margin	9.5	12.0	10.4	-4.6	3.7	10.2	9.2	22.4	28.4	28.1	9.9	8.1	7.9	6.3	8.2	9.1
Financing Income/(Expense) - Net	-42	-56	-59	-59	-61	-68	-64	-50	-16	10	10	7	14	7	3	-14
Profit before Taxes	4	3	5	-75	-39	6	31	336	533	571	225	189	182	138	184	226
Income Taxes	-1	1	2	-9	1	1	4	99	172	127	57	50	47	37	47	57
Profit after Tax	5	2	3	-67	-40	5	28	237	361	445	168	139	134	101	138	168
PAT Margin	1.0	0.3	0.6	-17.3	-6.9	0.7	2.8	14.0	19.1	22.6	7.7	6.3	6.3	4.9	5.9	6.7
EPS - Basic - ex Extraordinary Items	0.37	0.12	0.24	-3.34	-1.52	0.17	0.99	8.42	12.70	15.24	5.71	4.74	4.58	3.44	4.69	5.72
EPS - Diluted - ex Extraordinary Items	0.37	0.12	0.24	-3.34	-1.52	0.17	0.99	8.42	12.70	15.24	5.71	4.74	4.58	3.44	4.69	5.72
EBIT	45	58	58	-18	22	73	90	377	538	553	216	180	168	130	190	229
EBITDA	69	89	90	11	51	102	121	410	574	592	259	226	232	203	270	310
EBITDA Margin	14.6	18.5	16.1	2.9	8.9	14.4	12.3	24.3	30.3	30.1	11.9	10.2	10.9	9.7	11.6	12.3

Balance Sheet

Abridged

Understanding Balance Sheet

IOL Chemicals And Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	R 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	199	251	281	283	360	413	425	488	671	1,022	1,081	920	1,120	1,151	1,228
Long-Term Investments	-	-	-	0	0	0	2	7	5	21	205	250	66	25	52
Property Plant & Equipment - Net	571	462	443	407	402	395	412	438	488	560	662	833	1,021	1,179	1,262
Total Non-Current Assets	584	476	460	418	412	406	427	454	505	588	881	1,102	1,125	1,231	1,359
Total Assets	687	727	741	702	772	818	852	942	1,176	1,610	1,962	2,022	2,244	2,382	2,587
Total Current Liabilities	225	228	276	209	283	327	345	257	282	291	513	456	560	610	690
Long Term Debt	270	287	220	277	301	286	258	190	3	2	0	-	-	-	2
Total Non-Current Liabilities	288	326	255	286	304	302	292	211	80	59	57	58	73	85	98
Total Liabilities	513	554	532	494	587	629	636	468	362	350	570	514	633	694	788
Total Shareholders' Equity	174	173	209	207	184	189	216	474	814	1,260	1,392	1,508	1,612	1,688	1,799
Total Equity	174	173	209	207	184	189	216	474	814	1,260	1,392	1,508	1,612	1,688	1,799
Total Liabilities & Equity	687	727	741	702	772	818	852	942	1,176	1,610	1,962	2,022	2,244	2,382	2,587

Cash Flow

Abridged

Understanding Cash Flow Statement

IOL Chemicals And Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	29.29	31.60	35.83	-35.25	16.21	33.74	53.44	300.24	449.95	463.54	205.88	187.29	197.13	197.06	228.64
Working Capital - Increase/(Decrease)	-11.39	-32.25	-12.31	-52.83	-27.67	-17.45	5.95	-77.64	3.39	-76.51	-102.34	-63.69	90.33	-20.87	-17.22
Net CF from Operating Activities	17.90	-0.65	23.52	-88.09	-11.46	16.29	59.39	222.60	453.34	387.03	103.54	123.60	287.46	176.19	211.42
Capital Expenditures - Net	88.35	18.96	13.54	5.85	26.53	22.35	48.29	59.77	79.68	107.43	151.40	209.60	272.32	212.57	170.90
Net CF from Investing Activities	-88.35	-18.96	-13.54	-5.90	-28.68	-23.68	-51.65	-64.34	-188.49	-330.20	-138.79	-137.73	-204.76	-166.51	-209.74
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	-	20.57	23.48	35.22	23.50	29.35	23.48	29.35
Stock - Issuance/(Retirement) - Net	-	-	35.79	22.22	17.96	-	-	6.00	-	27.95	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	61.53	23.04	-45.16	69.70	21.78	-5.17	-24.81	-120.82	-229.60	-57.05	41.69	35.79	-47.05	84.28	14.85
Net Cash Flow from Financing Activities	61.53	23.04	-9.38	91.92	39.73	8.17	-8.76	-145.59	-250.17	-52.58	6.47	12.29	-76.40	60.80	-14.50
Free Cash Flow to Equity	-8.92	3.42	-35.19	-24.24	-16.21	-11.23	-13.71	42.01	144.06	222.55	-6.17	-50.21	-31.91	47.90	55.37
Free Operating CF net dividend	-70.77	-19.64	9.86	-94.00	-38.13	-6.13	11.03	162.07	352.49	255.34	-84.97	-111.72	-16.06	-60.84	9.08
Free Operating CF	-70.77	-19.64	9.86	-94.00	-38.13	-6.13	11.03	162.07	373.06	278.82	-49.75	-88.22	13.29	-37.36	38.43

Business Segment Analysis

FY End:

Mar 26

IOL Chemicals And Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Unallocated (47.5%)₹ 77.88 CrPharmaceutical (39.3%)₹ 64.38 CrChemicals (13.2%)₹ 21.67 Cr

Revenue / Sales

Pharmaceutical (54.2%)₹ 1,396.25 CrChemicals (45.0%)₹ 1,160.53 CrUnallocated (0.8%)₹ 21.38 Cr

Assets

Pharmaceutical (58.5%)₹ 1,512.64 CrChemicals (22.4%)₹ 578.66 CrUnallocated (19.2%)₹ 495.65 Cr

Regional Segment Analysis

FY End:

Mar 26

IOL Chemicals And Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (75.7%)₹ 1,754.79 CrRest of the world (20.0%)₹ 464.60 CrSwitzerland (2.3%)₹ 52.54 CrIndonesia (2.0%)₹ 47.13 Cr

Historical Segment Analysis

Track how IOL Chemicals And Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Business

Regional

Business

	2010 Mar 31	2019 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2010 Mar 31	2019 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Unallocated	3	4	21	23	62	88	65	78
Pharmaceutical	55	50	89	123	94	126	165	64
Chemicals	202	5	2	7	69	43	2	22

Frequently Asked Questions

What is the revenue of IOL Chemicals And Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of IOL Chemicals And Pharmaceuticals Ltd. is ₹ 2,523.63 Cr, reflecting a 1-year growth of 18.56% and a 3-year CAGR of 4.44%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of IOL Chemicals And Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of IOL Chemicals And Pharmaceuticals Ltd. is ₹ 168.11 Cr, with a 3-year earnings CAGR of 3.76%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of IOL Chemicals And Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of IOL Chemicals And Pharmaceuticals Ltd. is approximately ₹ 205.39 Cr (based on an operating margin of 8.14%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of IOL Chemicals And Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of IOL Chemicals And Pharmaceuticals Ltd. is 5.72. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of IOL Chemicals And Pharmaceuticals Ltd.?

The debt-to-equity ratio of IOL Chemicals And Pharmaceuticals Ltd. stands at 0.08. The interest coverage ratio is 16.37x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of IOL Chemicals And Pharmaceuticals Ltd.?

The estimated book value per share of IOL Chemicals And Pharmaceuticals Ltd. is 57.82 (derived from a P/B ratio of 2.80 and market price of ₹ 161.71), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of IOL Chemicals And Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of IOL Chemicals And Pharmaceuticals Ltd. is ₹ 211.42 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does IOL Chemicals And Pharmaceuticals Ltd. report consolidated or standalone financials?

IOL Chemicals And Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.